Abstract: The disclosure provides a highly efficient MOSCAP modulator that combines silicon photonics with transparent conducting oxide with on-chip wavelength division multiplexing capability. In at least one embodiment, a MOSCAP silicon microring modulator (Si-MRM) is heterogeneously integrated with a nano-sized silicon waveguide, a high dielectric constant insulator deposited on the silicon waveguide, and a high carrier mobility transparent conducting oxide (HMTCO) deposited on the insulator to form an array, gated by the HMTCO. The combination exhibits a high electro-optic modulation efficiency, a low V?·L, and consequently can be driven by a sub-volt Vpp at high modulation bandwidth. The utilization of HMTCO reduces the optical waveguide absorption, enabling a balanced Q-factor for sub-volt Vpp modulation while still supporting a large photon lifetime-limited bandwidth.

Abstract: Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.

Abstract: Embodiments of the present disclosure pertain to compounds that include: a molecule capable of binding to an ENL protein; and a ligand of an E3 ubiquitin ligase, where the molecule and the ligand are coupled to one another by a linker, a chemical bond, or combinations thereof. Additional embodiments of the present disclosure pertain to methods of treating or preventing a condition in a subject by administering to the subject a compound of the present disclosure. The condition to be treated or prevented may be associated with an ENL protein abnormality or facilitated by an ENL protein. Additional embodiments of the present disclosure pertain to methods of evaluating cellular activity by exposing a cell to a compound of the present disclosure.

Abstract: Embodiments of the disclosure concern devices comprised of resorbable, shape-memory foam configured to allow for healing at a desired location. In particular embodiments, use of the device at the location utilizes the inherent environment at the location to allow expansion of the device, resulting in an improved fit for the device. In specific cases, the device is a vaginal stent configured for use for pediatric or adolescent populations.

Abstract: Aspects of the disclosure concern methods and compositions related to recombinant microorganisms expressing one or more biologically active peptides that are heterologous to the microorganism, wherein the one or more biologically active peptides comprise a potassium channel blocker. In particular aspects, recombinant microorganisms are generated by introducing into the microorganism one or more polynucleotides encoding one or more biologically active peptides. In specific aspects, a subject having one or more diseases or conditions mediated by cells of the immune system and/or fibroblasts or fibroblast-like cells is administered a therapeutically effective amount of a recombinant microorganism or composition thereof, wherein the recombinant microorganism is capable of producing a therapeutically effective amount of the one or more biologically active polypeptides to treat or prevent the one or more diseases or conditions mediated by cells of the immune system and/or fibroblasts or fibroblast-like cells.

Abstract: Methods of data analysis, methods of detection, methods of treatment, compositions, and kits associated with treatment of diarrheal disorders are disclosed herein. Inventive concepts disclosed herein can assist stake holders in relieving patient suffering by identifying appropriate therapeutic regimens in an individualized and/or accurate manner.

Abstract: Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.

Abstract: Modified hydrophilic carbon clusters (HCCs), poly(ethylene glycol)-hydrophilic carbon clusters (PEG-HCCs) and similarly structured materials like graphene quantum dots (GQDs), PEGylated GQDs, small molecule antioxidants, and PEGylated small molecule antioxidants. These materials have been modified with an iron chelating moiety, deferoxamine, or a similar chelating moiety. By exploiting common binding sites, the carbon nanostructure facilitates intracellular transport including in mitochondria, reduces oxidative breakdown of the chelator moiety prior to treatment, and reduces both the cause and consequences of metal induced oxidative stress within the body thus providing a novel form of therapy for a range of oxidative and metal-related toxicities. Graphenic materials can be used for the treatment of acute and chronic mitochondrial electron transport chain dysfunction.

Abstract: Systems, methods, and devices for planning stereotactic surgical procedures are disclosed. In one aspect, a method includes: accessing surgical plans for previous stereotactic procedures performed on a group of patients, the surgical plans including imaging data representing an anatomical feature of each patient in the group; applying one or more transforms to register the imaging data for each patient to a template of the anatomical feature for the group of patients; generating one or more density maps for a trajectory targeting at least one region of interest (ROI) in the anatomical feature, based on the registered imaging data; and generating a surgical plan to perform a current stereotactic procedure on a subject patient, based on the one or more density maps, the surgical plan including the trajectory targeting the at least one ROI in the anatomical feature of the subject patient. Other aspects and features are also claimed and described.

Abstract: A disclosed radio frequency (RF) system, such as a cognitive radar, includes a software defined radio (SDR), an adaptive transmit amplifier, and a host computer. The system performs multi-dimensional optimization operations including selecting initial values for two or more configuration parameters, such as load impedance and input power. Disclosed methods iteratively perform image completion operations until a convergence criterion is satisfied. The image completion operations may include measuring a performance of the RF device to obtain a measured performance corresponding to the initial values of the configuration parameters, storing the measured performance as a point on a measured load-pull contour image, performing a load-pull extrapolation to extrapolate, from the configuration parameter values, predicted optimal values for the configuration parameters, and saving the predicted optimal values as the configuration parameter values for a next iteration of the image completion operations.

Abstract: Systems and methods for a multi-primary color system for display. A multi-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. One embodiment of the multi-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.

Abstract: The present invention includes systems and methods for a multi-primary color system for display. A multi-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. One embodiment of the multi-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.

Abstract: A system and method for determining fiber orientation within a layered composite using an eddy current probe is discussed. The eddy current probe includes an array of coils that are excited such that an effective pole of the end effector of the probe moves in a ring pattern. The eddy current probe is moved across the surface of a part such that a two-dimensional scan of the part is generated, analogous to a C-scan in ultrasonic testing. The eddy current probe is able to be used to determine the fiber orientation of a layered composite material by scanning at a single point on the material. The eddy current data is able to be fused with data from an ultrasonic transducer to produce a comprehensive view of the part.

Abstract: Embodiments provide a method for sequencing and assembling long DNA genomes comprising generating a 3D contact map of chromatin loop structures in a target genome, the 3D contact map of chromatin loop structures defining spatial proximity relationships between genomic loci in the genome, and deriving a linear genomic nucleic acid sequence from the 3D map of chromatin loop structures.

Abstract: Systems and methods for a multi-primary color system for display. A multi-primary color system increases the number of primary colors available in a color system and color system equipment. Increasing the number of primary colors reduces metameric errors from viewer to viewer. One embodiment of the multi-primary color system includes Red, Green, Blue, Cyan, Yellow, and Magenta primaries. The systems of the present invention maintain compatibility with existing color systems and equipment and provide systems for backwards compatibility with older color systems.

Abstract: Methods of treatment, methods of detection, and kits associated with ER?+ cancer, such as ER?+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifying cancer estrogen receptor status, and identifying appropriate therapeutic regimens in an individualized manner.

Abstract: Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.

Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

Abstract: An isolated human NKT cell or a plurality of cells thereof, having reduced or no detectable expression of endogenous beta-2-microglobulin (B2M); endogenous MHC class II-associated invariant chain (Ii); or both. Methods to generate the cell or cells, and methods of treatment using the cell or cells are also provided.

Abstract: The disclosure relates, in certain aspects, to compounds that can be used to inhibit ?-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-24, OXA-48, and/or OXA-58. In certain embodiments, these compounds can be used to inhibit activity of ?-lactamases in vitro and in vivo.